| Name | Title | Contact Details |
|---|
Rothenberger USA is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Athos is a venture-backed startup developing a revolutionary product for the fitness and athletic market. We are creating next generation wearable technology that gives you real insight into how your body works as you move and combining it with a beautiful user experience that will fit right into your existing routine. Our goal is to empower you to make more informed decisions while pursuing a healthy, active lifestyle.
Baystate Health is an integrated health care delivery system serving a population of nearly one million people in western Massachusetts. We are one of the largest health systems in New England with more than 12,000 employees, four hospitals, and over 80 medical practices. Baystate Medical Center has the only Level 1 Trauma Center in the region, and the only neonatal and pediatric intensive care units. University of Massachusetts Medical School-Baystate is the only regional campus of the University of Massachusetts Medical School. Baystate Medical Center has been ranked as one of the nation`s top hospitals for 2015-2016 by U.S. News & World Report and for the third time, Baystate Medical Center has been named a Magnet™ hospital for excellence in nursing services.
Sanomedics International Holdings, Inc. (SIMH) manufactures and distributes innovative professional medical, as well as, home health diagnostic devices and products.
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.